Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis

Free Radical Biology and Medicine

Volumn 108, Issue , 2017, Pages 610-626

  Toyokuni, Shinya ^a,b   Ito, Fumiya ^a   Yamashita, Kyoko ^a   Okazaki, Yasumasa ^a   Akatsuka, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Carcinogenesis; Ferroptosis; Iron; Redox signaling

Indexed keywords

ASCORBIC ACID; CYSTATHIONINE; FERROUS ION; IRON; NITRILOTRIACETATE IRON; THIOL; TRANSCRIPTION FACTOR NRF2; THIOL DERIVATIVE;

APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; COMPARATIVE STUDY; EPIGENETICS; EVIDENCE BASED PRACTICE; FERROPTOSIS; HUMAN; IRON TRANSPORT; KIDNEY CANCER; LOW TEMPERATURE; MALIGNANT NEOPLASM; METABOLOMICS; MITOCHONDRION; MOLECULAR BIOLOGY; NEXT GENERATION SEQUENCING; NONHUMAN; OXIDATION REDUCTION REACTION; PLASMA GAS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CELL DEATH; METABOLISM; NEOPLASM; OXIDATIVE STRESS;

ANIMALS; ASCORBIC ACID; CELL DEATH; HUMANS; IRON; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS;

EID: 85018770280     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.04.024     Document Type: Review

References (265)

1. [1] Heesterbeek, H., Anderson, R.M., Andreasen, V., Bansal, S., De Angelis, D., Dye, C., Eames, K.T., Edmunds, W.J., Frost, S.D., Funk, S., Modeling infectious disease dynamics in the complex landscape of global health. Science, 347, 2015 (aaa4339).
2. [2] Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E., Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. [3] Russell, D.G., Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2 (2001), 569–586.
4. [4] Marais, B., Gie, R., Schaaf, H., Hesseling, A., Obihara, C., Starke, J., Enarson, D., Donald, P., Beyers, N., The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era [state of the art]. Int. J. Tuberc. Lung Dis. 8 (2004), 392–402.
5. [5] Glaziou, P., Sismanidis, C., Floyd, K., Raviglione, M., Global epidemiology of tuberculosis. Cold Spring Harb. Persp. Med., 5, 2015, a017798.
6. [6] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA: Cancer J. Clin. 65 (2015), 5–29.
7. [7] Asghar, U., Witkiewicz, A.K., Turner, N.C., Knudsen, E.S., The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14 (2015), 130–146.
8. [8] Carvalho, S., Levi‐Schaffer, F., Sela, M., Yarden, Y., Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18. Br. J. Pharmacol. 173 (2016), 1407–1424.
9. [9] Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D.R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med., 7, 2015, 283ra53.
10. [10] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
11. [11] Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18 (2012), 378–381.
12. [12] Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J.A., Balasubramanian, S., Bloom, T., Brennan, K.W., Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18 (2012), 382–384.
13. [13] Hauschild, A., Grob, J.-J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, W.H., Kaempgen, E., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
14. [14] McArthur, G.A., Chapman, P.B., Robert, C., Larkin, J., Haanen, J.B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P.A., Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15 (2014), 323–332.
15. [15] Kantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M.B., Ravandi, F., Faderl, S., Kadia, T., Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119 (2012), 1981–1987.
16. [16] Corless, C.L., Ballman, K.V., Antonescu, C.R., Kolesnikova, V., Maki, R.G., Pisters, P.W., Blackstein, M.E., Blanke, C.D., Demetri, G.D., Heinrich, M.C., Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J. Clin. Oncol. 32 (2014), 1563–1570.
17. [17] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
18. [18] Koboldt, D.C., Steinberg, K.M., Larson, D.E., Wilson, R.K., Mardis, E.R., The next-generation sequencing revolution and its impact on genomics. Cell 155:1 (2013), 27–38.
19. [19] Collins, F.S., Morgan, M., Patrinos, A., The Human Genome Project: lessons from large-scale biology. Science 300 (2003), 286–290.
20. [20] Gibbs, R.A., Belmont, J.W., Hardenbol, P., Willis, T.D., Yu, F., Yang, H., Ch'ang, L.-Y., Huang, W., Liu, B., Shen, Y., The international HapMap project. Nature 426 (2003), 789–796.
21. [21] International Cancer Genome Consortium Mutation Pathways: consequences Subgroup of the Bioinformatics Analyses Working Group. Computational approaches to identify functional genetic variants in cancer genomes. Nat. Methods 10 (2013), 723–729.
22. [22] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., Boyault, S., Burkhardt, B., Butler, A.P., Caldas, C., Davies, H.R., Desmedt, C., Eils, R., Eyfjord, J.E., Foekens, J.A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jager, N., Jones, D.T., Jones, D., Knappskog, S., Kool, M., Lakhani, S.R., Lopez-Otin, C., Martin, S., Munshi, N.C., Nakamura, H., Northcott, P.A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J.V., Puente, X.S., Raine, K., Ramakrishna, M., Richardson, A.L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T.N., Span, P.N., Teague, J.W., Totoki, Y., Tutt, A.N., Valdes-Mas, R., van Buuren, M.M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L.R., Australian Pancreatic Cancer Genome, I., Consortium, I.B.C., Consortium, I.M.-S., PedBrain, I., Zucman-Rossi, J., Futreal, P.A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S.M., Siebert, R., Campo, E., Shibata, T., Pfister, S.M., Campbell, P.J., Stratton, M.R., Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
23. [23] Matsumoto, Y., Marusawa, H., Kinoshita, K., Endo, Y., Kou, T., Morisawa, T., Azuma, T., Okazaki, I.M., Honjo, T., Chiba, T., Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 13 (2007), 470–476.
24. [24] Shimizu, T., Marusawa, H., Endo, Y., Chiba, T., Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci. 103 (2012), 1201–1206.
25. [25] Olinski, R., Starczak, M., Gackowski, D., Enigmatic 5-hydroxymethyluracil: oxidatively modified base, epigenetic mark or both?. Mutat. Res./Rev. Mutat. Res. 767 (2016), 59–66.
26. [26] Toyokuni, S., Oxidative stress as an iceberg in carcinogenesis and cancer biology. Arch. Biochem. Biophys. 595 (2016), 46–49.
27. [27] Toyokuni, S., The origin and future of oxidative stress pathology: from the recognition of carcinogenesis as an iron addiction with ferroptosis-resistance to non-thermal plasma therapy. Pathol. Int. 66 (2016), 245–259.
28. [28] Olson, K.R., Straub, K.D., The role of hydrogen sulfide in evolution and the evolution of hydrogen sulfide in metabolism and signaling. Physiology 31 (2016), 60–72.
29. [29] Biemond, P., van Eijk, H.G., Swaak, A.J., Koster, J.F., Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J. Clin. Invest. 73 (1984), 1576–1579.
30. [30] Loeb, L.A., Bielas, J.H., Beckman, R.A., Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68 (2008), 3551–3557.
31. [31] Toyokuni, S., Okamoto, K., Yodoi, J., Hiai, H., Persistent oxidative stress in cancer. FEBS Lett. 358 (1995), 1–3.
32. [32] Cadet, J., Loft, S., Olinski, R., Evans, M.D., Bialkowski, K., Richard Wagner, J., Dedon, P.C., Moller, P., Greenberg, M.M., Cooke, M.S., Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids. Free Radic. Res. 46 (2012), 367–381.
33. [33] Kasai, H., Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat. Res. 387 (1997), 147–163.
34. [34] Kondo, S., Toyokuni, S., Iwasa, Y., Tanaka, T., Onodera, H., Hiai, H., Imamura, M., Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic. Biol. Med. 27 (1999), 401–410.
35. [35] Kondo, S., Toyokuni, S., Tanaka, T., Hiai, H., Onodera, H., Kasai, H., Imamura, M., Overexpression of the hOGG1 gene and high 8-hydroxy-2′-deoxyguanosine (8-OHdG) lyase activity in human colorectal carcinoma: regulation mechanism of the 8-OHdG level in DNA. Clin. Cancer Res. 6 (2000), 1394–1400.
36. [36] Okamoto, K., Toyokuni, S., Kim, W.J., Ogawa, O., Kakehi, Y., Arao, S., Hiai, H., Yoshida, O., Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Int. J. Cancer 65 (1996), 437–441.
37. [37] Ushio-Fukai, M., Nakamura, Y., Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 266 (2008), 37–52.
38. [38] Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.-T., Giaccia, A.J., Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009), 35–44.
39. [39] Chen, Z., Pervaiz, S., Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ. 17 (2010), 408–420.
40. [40] Wu, J.B., Shao, C., Li, X., Li, Q., Hu, P., Shi, C., Li, Y., Chen, Y.-T., Yin, F., Liao, C.-P., Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J. Clin. Invest. 124 (2014), 2891–2908.
41. [41] Liu, C.-Y., Xu, J.-Y., Shi, X.-Y., Huang, W., Ruan, T.-Y., Xie, P., Ding, J.-L., M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab. Invest. 93 (2013), 844–854.
42. [42] Dijkgraaf, E.M., Heusinkveld, M., Tummers, B., Vogelpoel, L.T., Goedemans, R., Jha, V., Nortier, J.W., Welters, M.J., Kroep, J.R., van der Burg, S.H., Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73 (2013), 2480–2492.
43. [43] Hughes, R., Qian, B.-Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O.C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 75 (2015), 3479–3491.
44. [44] Shukla, A., Edwards, R., Yang, Y., Hahn, A., Folkers, K., Ding, J., Padmakumar, V., Cataisson, C., Suh, K., Yuspa, S., CLIC4 regulates TGF-β-dependent myofibroblast differentiation to produce a cancer stroma. Oncogene 33 (2014), 842–850.
45. [45] Pesic, M., Greten, F.R., Inflammation and cancer: tissue regeneration gone awry. Curr. Opin. Cell Biol. 43 (2016), 55–61.
46. [46] Özdemir, B.C., Pentcheva-Hoang, T., Carstens, J.L., Zheng, X., Wu, C.-C., Simpson, T.R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S.V., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 (2014), 719–734.
47. [47] Shibata, T., Ohta, T., Tong, K.I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., Hirohashi, S., Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 105 (2008), 13568–13573.
48. [48] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
49. [49] Suzuki, T., Motohashi, H., Yamamoto, M., Toward clinical application of the Keap1–Nrf2 pathway. Trends Pharmacol. Sci. 34 (2013), 340–346.
50. [50] Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonen, A.-L., The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 1 (2013), 45–49.
51. [51] Moi, P., Chan, K., Asunis, I., Cao, A., Kan, Y.W., Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 91 (1994), 9926–9930.
52. [52] Tsai, J.J., Dudakov, J.A., Takahashi, K., Shieh, J.-H., Velardi, E., Holland, A.M., Singer, N.V., West, M.L., Smith, O.M., Young, L.F., Nrf2 regulates haematopoietic stem cell function. Nat. Cell Biol. 15 (2013), 309–316.
53. [53] Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M., Nabeshima, Y., An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236 (1997), 313–322.
54. [54] Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D., Yamamoto, M., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13 (1999), 76–86.
55. [55] Andrews, N.C., Erdjument-Bromage, H., Davidson, M.B., Tempst, P., Orkin, S.H., Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 362 (1993), 722–728.
56. [56] Shivdasani, R.A., Orkin, S.H., Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc. Natl. Acad. Sci. USA 92 (1995), 8690–8694.
57. [57] Pischedda, C., Cocco, S., Melis, A., Marini, M.G., Kan, Y.W., Cao, A., Moi, P., Isolation of a differentially regulated splicing isoform of human NF-E2. Proc. Natl. Acad. Sci. USA 92 (1995), 3511–3515.
58. [58] Ponta, H., Sherman, L., Herrlich, P.A., CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4 (2003), 33–45.
59. [59] Zoller, M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 11 (2011), 254–267.
60. [60] Bannai, S., Kitamura, E., Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J. Biol. Chem. 255 (1980), 2372–2376.
61. [61] Sato, H., Tamba, M., Ishii, T., Bannai, S., Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274 (1999), 11455–11458.
62. c− and thereby promotes tumor growth. Cancer Cell 19 (2011), 387–400.
63. [63] Tanabe, K.K., Ellis, L.M., Saya, H., Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341 (1993), 725–726.
64. [64] Rall, C.J., Rustgi, A.K., CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res. 55 (1995), 1831–1835.
65. [65] Muramaki, M., Miyake, H., Kamidono, S., Hara, I., Over expression of CD44V8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression. J. Urol. 171 (2004), 426–430.
66. [66] Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., Onishi, N., Masuko, T., Yoshizawa, K., Kawashiri, S., Mukai, M., Asoda, S., Kawana, H., Nakagawa, T., Saya, H., Nagano, O., xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 73 (2013), 1855–1866.
67. [67] Zeilstra, J., Joosten, S.P., van Andel, H., Tolg, C., Berns, A., Snoek, M., van de Wetering, M., Spaargaren, M., Clevers, H., Pals, S.T., Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene 33 (2013), 665–670.
68. [68] Nagano, O., Okazaki, S., Saya, H., Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32 (2013), 5191–5198.
69. [69] Lau, W.M., Teng, E., Chong, H.S., Lopez, K.A., Tay, A.Y., Salto-Tellez, M., Shabbir, A., So, J.B., Chan, S.L., CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 74 (2014), 2630–2641.
70. [70] Chew, S.H., Okazaki, Y., Akatsuka, S., Wang, S., JIang, L., Ohara, Y., Ito, F., Saya, H., Sekido, Y., Toyokuni, S., Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma. Free Radic. Biol. Med. 106 (2017), 91–99.
71. [71] Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H.J., van Es, J.H., Sato, T., Stange, D.E., Begthel, H., van den Born, M., Danenberg, E., van den Brink, S., Korving, J., Abo, A., Peters, P.J., Wright, N., Poulsom, R., Clevers, H., Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6 (2010), 25–36.
72. [72] Jiang, L., Yamashita, Y., Chew, S.H., Akatsuka, S., Ukai, S., Wang, S., Nagai, H., Okazaki, Y., Takahashi, T., Toyokuni, S., Connective tissue growth factor and β‐catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. J. Pathol. 233 (2014), 402–414.
73. [73] Uematsu, K., Kanazawa, S., You, L., He, B., Xu, Z., Li, K., Peterlin, B.M., McCormick, F., Jablons, D.M., Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 63 (2003), 4547–4551.
74. [74] Mazieres, J., You, L., He, B., Xu, Z., Twogood, S., Lee, A.Y., Reguart, N., Batra, S., Mikami, I., Jablons, D.M., Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer 117 (2005), 326–332.
75. [75] Harris, I.S., Treloar, A.E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K.C., Yung, K.Y., Brenner, D., Knobbe-Thomsen, C.B., Cox, M.A., Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222.
76. [76] Benhar, M., Shytaj, I.L., Stamler, J.S., Savarino, A., Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J. Clin. Invest. 126 (2016), 1630–1639.
77. [77] Uphoff, S., Lord, N.D., Okumus, B., Potvin-Trottier, L., Sherratt, D.J., Paulsson, J., Stochastic activation of a DNA damage response causes cell-to-cell mutation rate variation. Science 351 (2016), 1094–1097.
78. [78] Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A.L., Pronzato, M.A., Marinari, U.M., Domenicotti, C., Role of glutathione in cancer progression and chemoresistance. Oxid. Med. Cell. Longev., 2013, 2013, 972913.
79. [79] Arner, E.S., Holmgren, A., The thioredoxin system in cancer. Semin. Cancer Biol. 16 (2006), 420–426.
80. [80] Zhang, Q., Vakili, M.R., Li, X.-F., Lavasanifar, A., Le, X.C., Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells. Biomaterials 35 (2014), 7088–7100.
81. [81] Surnar, B., Sharma, K., Jayakannan, M., Core–shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells. Nanoscale 7 (2015), 17964–17979.
82. [82] Gunshin, H., Mackenzie, B., Berger, U., Gunshin, Y., Romero, M., Boron, W., Nussberger, S., Gollan, J., Hediger, M., Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 (1997), 482–488.
83. [83] Andrews, N.C., The iron transporter DMT1. Int. J. Biochem. Cell Biol. 31 (1999), 991–994.
84. [84] Toyokuni, S., Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 100 (2009), 9–16.
85. [85] Toyokuni, S., Iron-induced carcinogenesis: the role of redox regulation. Free Radic. Biol. Med. 20 (1996), 553–566.
86. [86] Zacharski, L., Chow, B., Howes, P., Shamayeva, G., Baron, J., Dalman, R., Malenka, D., Ozaki, C., Levori, P., Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J. Natl. Cancer Inst. 100 (2008), 996–1002.
87. [87] Kato, J., Kobune, M., Nakamura, T., Kuroiwa, G., Takada, K., Takimoto, R., Sato, Y., Fujikawa, K., Takahashi, M., Takayama, T., Ikeda, T., Niitsu, Y., Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 61 (2001), 8697–8702.
88. [88] Kato, J., Miyanishi, K., Kobune, M., Nakamura, T., Takada, K., Takimoto, R., Kawano, Y., Takahashi, S., Takahashi, M., Sato, Y., Takayama, T., Niitsu, Y., Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 42 (2007), 830–836.
89. [89] Shirase, T., Mori, K., Okazaki, Y., Itoh, K., Yamamoto, M., Tabuchi, M., Kishi, F., Jiang, L., Akatsuka, S., Nakao, K., Toyokuni, S., Suppression of SLC11A2 expression is essential to maintain duodenal integrity during dietary iron overload. Am. J. Pathol. 177 (2010), 677–685.
90. [90] Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc. Natl. Acad. Sci. USA 112 (2015), 13982–13987.
91. [91] Ben-David, U., Ha, G., Khadka, P., Jin, X., Wong, B., Franke, L., Golub, T.R., The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nat. Commun., 7, 2016, 12160.
92. [92] Garber, J.E., Offit, K., Hereditary cancer predisposition syndromes. J. Clin. Oncol. 23 (2005), 276–292.
93. [93] Ebina, Y., Okada, S., Hamazaki, S., Ogino, F., Li, J.L., Midorikawa, O., Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. J. Natl. Cancer Inst. 76 (1986), 107–113.
94. [94] Nishiyama, Y., Suwa, H., Okamoto, K., Fukumoto, M., Hiai, H., Toyokuni, S., Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn. J. Cancer Res. 86 (1995), 1150–1158.
95. [95] Okada, S., Iron-induced tissue damage and cancer: the role of reactive oxygen free radicals. Pathol. Int. 46 (1996), 311–332.
96. INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 18 (1999), 3793–3797.
97. [97] Li, J.L., Okada, S., Hamazaki, S., Ebina, Y., Midorikawa, O., Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 47 (1987), 1867–1869.
98. [98] Hamazaki, S., Okada, S., Ebina, Y., Midorikawa, O., Acute renal failure and glucosuria induced by ferric nitrilotriacetate in rats. Toxicol. Appl. Pharmacol. 77 (1985), 267–274.
99. [99] Hamazaki, S., Okada, S., Ebina, Y., Fujioka, M., Midorikawa, O., Nephrotoxicity of ferric nitrilotriacetate: an electron-microscopic and metabolic study. Am. J. Pathol. 123 (1986), 343–350.
100. [100] Okada, S., Hamazaki, S., Ebina, Y., Li, J.-L., Midorikawa, O., Nephrotoxicity and its prevention by vitamin E on ferric nitrilotriacetate-promoted lipid peroxidation. Biochim. Biophys. Acta 922 (1987), 28–33.
101. [101] Toyokuni, S., Okada, S., Hamazaki, S., Minamiyama, Y., Yamada, Y., Liang, P., Fukunaga, Y., Midorikawa, O., Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res. 50 (1990), 5574–5580.
102. [102] Toyokuni, S., Uchida, K., Okamoto, K., Hattori-Nakakuki, Y., Hiai, H., Stadtman, E.R., Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc. Natl. Acad. Sci. USA 91 (1994), 2616–2620.
103. [103] Toyokuni, S., Mori, T., Dizdaroglu, M., DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int. J. Cancer 57 (1994), 123–128.
104. [104] Fukuda, A., Osawa, T., Hitomi, K., Uchida, K., 4-Hydroxy-2-nonenal cytotoxicity in renal proximal tubular cells: protein modification and redox alteration. Arch. Biochem. Biophys. 333 (1996), 419–426.
105. [105] Fukuda, A., Osawa, T., Tanaka, T., Toyokuni, S., Uchida, K., Oxidative stress response in iron-induced acute nephrotoxicity: enhanced expression of heat shock protein 90. Biochem. Biophys. Res. Commun. 219 (1996), 76–81.
106. [106] Satoh, K., Yamada, S., Koike, Y., Igarashi, Y., Toyokuni, S., Kumano, T., Takahata, T., Hayakari, M., Tsuchida, S., Uchida, K., A 1-hour enzyme-linked immunosorbent assay for quantitation of acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal. Biochem. 270 (1999), 323–328.
107. [107] Okada, K., Wangpoengtrakul, C., Osawa, T., Toyokuni, S., Tanaka, K., Uchida, K., 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 274 (1999), 23787–23793.
108. [108] Toyokuni, S., Iwasa, Y., Kondo, S., Tanaka, T., Ochi, H., Hiai, H., Intranuclear distribution of 8-hydroxy-2′-deoxyguanosine: an immunocytochemical study. J. Histochem. Cytochem. 47 (1999), 833–835.
109. [109] Tanaka, T., Kondo, S., Iwasa, Y., Hiai, H., Toyokuni, S., Expression of stress-response and cell proliferation genes in renal cell carcinoma induced by oxidative stress. Am. J. Pathol. 156 (2000), 2149–2157.
110. [110] Kawai, Y., Furuhata, A., Toyokuni, S., Aratani, Y., Uchida, K., Formation of acrolein-derived 2′-deoxyadenosine adduct in an iron-induced carcinogenesis model. J. Biol. Chem. 278 (2003), 50346–50354.
111. [111] Hashimoto, M., Sibata, T., Wasada, H., Toyokuni, S., Uchida, K., Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct. J. Biol. Chem. 278 (2003), 5044–5051.
112. [112] Ozeki, M., Miyagawa-Hayashino, A., Akatsuka, S., Shirase, T., Lee, W.H., Uchida, K., Toyokuni, S., Susceptibility of actin to modification by 4-hydroxy-2-nonenal. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 827 (2005), 119–126.
113. 2-mediated covalent modification of protein by lipid peroxidation-derived saturated aldehydes. Chem. Res. Toxicol. 21 (2008), 1261–1270.
114. [114] Okada, S., Minamiyama, Y., Hamazaki, S., Toyokuni, S., Sotomatsu, A., Glutathione cycle dependency of ferric nitrilotriacetate-induced lipid peroxidation in mouse proximal renal tubules. Arch. Biochem. Biophys. 301 (1993), 138–142.
115. [115] Toyokuni, S., Masumizu, T., Ozeki, M., Kondo, S., Hiroyasu, M., Kohno, M., Hiai, H., An electron spin resonance study on alkylperoxyl radical in thin-sliced renal tissues from ferric nitrilotriacetate-treated rats: the effect of alpha-tocopherol feeding. Free Radic. Res. 35 (2001), 245–255.
116. [116] Uchida, K., Fukuda, A., Kawakishi, S., Hiai, H., Toyokuni, S., A renal carcinogen ferric nitrilotriacetate mediates a temporary accumulation of aldehyde-modified proteins within cytosolic compartment of rat kidney. Arch. Biochem. Biophys. 317 (1995), 405–411.
117. [117] Toyokuni, S., Luo, X.P., Tanaka, T., Uchida, K., Hiai, H., Lehotay, D.C., Induction of a wide range of C2-12 aldehydes and C7-12 acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic. Biol. Med. 22 (1997), 1019–1027.
118. [118] Toyokuni, S., Tanaka, T., Hattori, Y., Nishiyama, Y., Ochi, H., Hiai, H., Uchida, K., Osawa, T., Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest. 76 (1997), 365–374.
119. [119] Tanaka, T., Nishiyama, Y., Okada, K., Hirota, K., Matsui, M., Yodoi, J., Hiai, H., Toyokuni, S., Induction and nuclear translocation of thioredoxin by oxidative damage in the mouse kidney: independence of tubular necrosis and sulfhydryl depletion. Lab. Invest. 77 (1997), 145–155.
120. [120] Toyokuni, S., Sagripanti, J.L., Iron-mediated DNA damage: sensitive detection of DNA strand breakage catalyzed by iron. J. Inorg. Biochem. 47 (1992), 241–248.
121. [121] Toyokuni, S., Sagripanti, J.-L., DNA single- and double-strand breaks produced by ferric nitrilotriacetate in relation to renal tubular carcinogenesis. Carcinogenesis 14 (1993), 223–227.
122. [122] Toyokuni, S., Mori, T., Hiai, H., Dizdaroglu, M., Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int. J. Cancer 62 (1995), 309–313.
123. [123] ESCODD, Comparative analysis of baseline 8-oxo-7,8-dihydroguanine in mammalian cell DNA, by different methods in different laboratories: an approach to consensus. Carcinogenesis 23 (2002), 2129–2133.
124. [124] Sies, H., German-Japanese relationships in biochemistry: a personal perspective. Nagoya J. Med. Sci. 78 (2016), 335–347.
125. [125] Toyokuni, S., Reactive oxygen species-induced molecular damage and its application in pathology. Pathol. Int. 49 (1999), 91–102.
126. [126] Hiroyasu, M., Ozeki, M., Kohda, H., Echizenya, M., Tanaka, T., Hiai, H., Toyokuni, S., Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am. J. Pathol. 160 (2002), 419–424.
127. [127] Vogelstein, B., Kinzler, K.W., The Genetic Basis of Human Cancer. 1998, McGraw-Hill, New York.
128. [128] Akatsuka, S., Yamashita, Y., Ohara, H., Liu, Y.T., Izumiya, M., Abe, K., Ochiai, M., Jiang, L., Nagai, H., Okazaki, Y., Murakami, H., Sekido, Y., Arai, E., Kanai, Y., Hino, O., Takahashi, T., Nakagama, H., Toyokuni, S., Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One, 7, 2012, e43403.
129. [129] Liu, Y.-T., Shang, D.-G., Akatsuka, S., Ohara, H., Dutta, K.K., Mizushima, K., Naito, Y., Yoshikawa, T., Izumiya, M., Abe, K., Nakagama, H., Noguchi, N., Toyokuni, S., Chronic oxidative stress causes amplification and overexpresson of ptprz1 protein tyrosine phosphatase to activate b-catenin pathway. Am. J. Pathol. 171 (2007), 1978–1988.
130. [130] Bao, Z.S., Chen, H.M., Yang, M.Y., Zhang, C.B., Yu, K., Ye, W.L., Hu, B.Q., Yan, W., Zhang, W., Akers, J., Ramakrishnan, V., Li, J., Carter, B., Liu, Y.W., Hu, H.M., Wang, Z., Li, M.Y., Yao, K., Qiu, X.G., Kang, C.S., You, Y.P., Fan, X.L., Song, W.S., Li, R.Q., Su, X.D., Chen, C.C., Jiang, T., RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24 (2014), 1765–1773.
131. [131] Maser, R.S., Choudhury, B., Campbell, P.J., Feng, B., Wong, K.-K., Protopopov, A., O'Neil, J., Gutierrez, A., Ivanova, E., Perna, I., Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447 (2007), 966–971.
132. [132] Edwards, J.H., The Oxford Grid. Ann. Hum. Genet. 55 (1991), 17–31.
133. [133] Toyokuni, S., Mechanisms of asbestos-induced carcinogenesis. Nagoya J. Med. Sci. 71 (2009), 1–10.
134. [134] Nagai, H., Ishihara, T., Lee, W.H., Ohara, H., Okazaki, Y., Okawa, K., Toyokuni, S., Asbestos surface provides a niche for oxidative modification. Cancer Sci. 102 (2011), 2118–2125.
135. [135] Jiang, L., Akatsuka, S., Nagai, H., Chew, S.H., Ohara, H., Okazaki, Y., Yamashita, Y., Yoshikawa, Y., Yasui, H., Ikuta, K., Sasaki, K., Kohgo, Y., Hirano, S., Shinohara, Y., Kohyama, N., Takahashi, T., Toyokuni, S., Iron overload signature in chrysotile-induced malignant mesothelioma. J. Pathol. 228 (2012), 366–377.
136. [136] Chew, S.H., Toyokuni, S., Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic. Biol. Med. 86 (2015), 166–178.
137. [137] Nagai, H., Okazaki, Y., Chew, S., Misawa, N., Yamashita, Y., Akatsuka, S., Yamashita, K., Ishihara, T., Yoshikawa, Y., Jiang, L., Ohara, H., Takahashi, T., Ichihara, G., Kostarelos, K., Miyata, Y., Shinohara, H., Toyokuni, S., Diameter of multi-walled carbon nanotubes is a critical factor in mesothelial injury and subsequent carcinogenesis. Proc. Natl. Acad. Sci. USA 108 (2011), E1330–E1338.
138. [138] Toyokuni, S., Genotoxicity and carcinogenicity risk of carbon nanotubes. Adv. Drug Deliv. Rev. 65 (2013), 2098–2110.
139. [139] Toyokuni, S., Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep. 7 (2002), 189–197.
140. [140] Toyokuni, S., Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB Life 60 (2008), 441–447.
141. [141] Toyokuni, S., Mysterious link between iron overload and CDKN2A/2B. J. Clin. Biochem. Nutr. 48 (2011), 46–49.
142. [142] Toyokuni, S., Akatsuka, S., What has been learned from the studies of oxidative stress-induced carcinogenesis: proposal of the concept of oxygenomics. J. Clin. Biochem. Nutr. 39 (2006), 3–10.
143. [143] Aruoma, O.I., Halliwell, B., (eds.) DNA and Free Radicals: Techniques, Mechanisms and Applications, 1998, OICA International, Saint Lucia/London.
144. [144] Toyokuni, S., Sagripanti, J.-L., Association between 8-hydroxy-2′-deoxyguanosine formation and DNA strand breaks mediated by copper and iron. Free Radic. Biol. Med. 20 (1996), 859–864.
145. [145] Akatsuka, S., Toyokuni, S., Genome-scale approaches to investigate oxidative DNA damage. J. Clin. Biochem. Nutr. 47 (2010), 91–97.
146. [146] Akatsuka, S., Aung, T.T., Dutta, K.K., Jiang, L., Lee, W.H., Liu, Y.T., Onuki, J., Shirase, T., Yamasaki, K., Ochi, H., Naito, Y., Yoshikawa, T., Kasai, H., Tominaga, Y., Sakumi, K., Nakabeppu, Y., Kawai, Y., Uchida, K., Yamasaki, A., Tsuruyama, T., Yamada, Y., Toyokuni, S., Contrasting genome-wide distribution of 8-hydroxyguanine and acrolein-modified adenine during oxidative stress-induced renal carcinogenesis. Am. J. Pathol. 169 (2006), 1328–1342.
147. [147] Cremer, T., Cremer, C., Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat. Rev. Genet. 2 (2001), 292–301.
148. [148] Tanabe, H., Muller, S., Neusser, M., von Hase, J., Calcagno, E., Cremer, M., Solovei, I., Cremer, C., Cremer, T., Evolutionary conservation of chromosome territory arrangements in cell nuclei from higher primates. Proc. Natl. Acad. Sci. USA 99 (2002), 4424–4429.
149. [149] Yoshihara, M., Jiang, L., Akatsuka, S., Suyama, M., Toyokuni, S., Genome-wide profiling of 8-oxoguanine reveals its association with spatial positioning in nucleus. DNA Res. 21 (2014), 603–612.
150. [150] Chew, S.H., Okazaki, Y., Nagai, H., Misawa, N., Akatsuka, S., Yamashita, K., Jiang, L., Yamashita, Y., Noguchi, M., Hosoda, K., Sekido, Y., Takahashi, T., Toyokuni, S., Cancer-promoting role of adipocytes in asbestos-induced mesothelial carcinogenesis through dysregulated adipocytokine production. Carcinogenesis 35 (2013), 164–172.
151. [151] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
152. [152] Ursini, F., Maiorino, M., Valente, M., Ferri, L., Gregolin, C., Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim. Biophys. Acta (BBA) Lipids Lipid Meteb. 710 (1982), 197–211.
153. [153] Nomura, K., Imai, H., Koumura, T., Arai, M., Nakagawa, Y., Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. J. Biol. Chem. 274 (1999), 29294–29302.
154. [154] Nomura, K., Imai, H., Koumura, T., Kobayashi, T., Nakagawa, Y., Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem. J. 351:Pt 1 (2000), 183–193.
155. [155] Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
156. [156] Imai, H., Hirao, F., Sakamoto, T., Sekine, K., Mizukura, Y., Saito, M., Kitamoto, T., Hayasaka, M., Hanaoka, K., Nakagawa, Y., Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. Biochem. Biophys. Res. Commun. 305 (2003), 278–286.
157. [157] Imai, H., Hakkaku, N., Iwamoto, R., Suzuki, J., Suzuki, T., Tajima, Y., Konishi, K., Minami, S., Ichinose, S., Ishizaka, K., Shioda, S., Arata, S., Nishimura, M., Naito, S., Nakagawa, Y., Depletion of selenoprotein GPx4 in spermatocytes causes male infertility in mice. J. Biol. Chem. 284 (2009), 32522–32532.
158. [158] Imai, H., Suzuki, K., Ishizaka, K., Ichinose, S., Oshima, H., Okayasu, I., Emoto, K., Umeda, M., Nakagawa, Y., Failure of the expression of phospholipid hydroperoxide glutathione peroxidase in the spermatozoa of human infertile males. Biol. Reprod. 64 (2001), 674–683.
159. [159] Imai, H., Nakagawa, Y., Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic. Biol. Med. 34 (2003), 145–169.
160. [160] Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16 (2014), 1180–1191.
161. [161] Okamoto, K., Toyokuni, S., Uchida, K., Ogawa, O., Takenewa, J., Kakehi, Y., Kinoshita, H., Hattori-Nakakuki, Y., Hiai, H., Yoshida, O., Formation of 8-hydroxy-2′-deoxyguanosine and 4-hydroxy-2-nonenal- modified proteins in human renal-cell carcinoma. Int. J. Cancer 58 (1994), 825–829.
162. [162] Toyokuni, S., Iron as a target of chemoprevention for longevity in humans. Free Radic. Res. 45 (2011), 906–917.
163. [163] Spitz, D.R., Sim, J.E., Ridnour, L.A., Galoforo, S.S., Lee, Y.J., Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann. N. Y. Acad. Sci. 899 (2000), 349–362.
164. [164] Boroughs, L.K., DeBerardinis, R.J., Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17 (2015), 351–359.
165. [165] DeBerardinis, R.J., Cheng, T., Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29 (2010), 313–324.
166. [166] Cetinbas, N.M., Sudderth, J., Harris, R.C., Cebeci, A., Negri, G.L., Yilmaz, O.H., DeBerardinis, R.J., Sorensen, P.H., Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. Sci. Rep., 6, 2016, 32606.
167. [167] Commisso, C., Davidson, S.M., Soydaner-Azeloglu, R.G., Parker, S.J., Kamphorst, J.J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J.A., Thompson, C.B., Rabinowitz, J.D., Metallo, C.M., Vander Heiden, M.G., Bar-Sagi, D., Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497 (2013), 633–637.
168. [168] Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J.M., Dell'antonio, G., Mautner, J., Tonon, G., Haigis, M., Shirihai, O.S., Doglioni, C., Bardeesy, N., Kimmelman, A.C., Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25 (2011), 717–729.
169. [169] Doll, S., Proneth, B., Tyurina, Y.Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., Prokisch, H., Trumbach, D., Mao, G., Qu, F., Bayir, H., Fullekrug, J., Scheel, C.H., Wurst, W., Schick, J.A., Kagan, V.E., Angeli, J.P., Conrad, M., ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13 (2017), 91–98.
170. [170] Kagan, V.E., Mao, G., Qu, F., Angeli, J.P., Doll, S., Croix, C.S., Dar, H.H., Liu, B., Tyurin, V.A., Ritov, V.B., Kapralov, A.A., Amoscato, A.A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., Bahar, I., Greenberger, J., Mallampalli, R.K., Stockwell, B.R., Tyurina, Y.Y., Conrad, M., Bayir, H., Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13 (2017), 81–90.
171. [171] Okada, S., Midorikawa, O., Induction of rat renal adenocarcinoma by Fe-nitrilotriacetate (Fe-NTA). Jpn. Arch. Intern. Med. 29 (1982), 485–491.
172. [172] Esworthy, R.S., Doan, K., Doroshow, J.H., Chu, F.F., Cloning and sequencing of the cDNA encoding a human testis phospholipid hydroperoxide glutathione peroxidase. Gene 144 (1994), 317–318.
173. [173] Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E.K., Culmsee, C., Plesnila, N., Kremmer, E., Radmark, O., Wurst, W., Bornkamm, G.W., Schweizer, U., Conrad, M., Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8 (2008), 237–248.
174. [174] Gutteridge, J., Rowley, D., Halliwell, B., Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of ‘free’ iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem. J. 199 (1981), 263–265.
175. [175] Hirayama, T., Okuda, K., Nagasawa, H., A highly selective turn-on fluorescent probe fro iron(II) to visualize labile iron in living cells. Chem. Sci. 4 (2013), 1250–1256.
176. [176] Hirayama, T., Nagasawa, H., Chemical tools for detecting Fe ions. J. Clin. Biochem. Nutr. 60 (2017), 39–48.
177. [177] Mukaide, T., Hattori, Y., Misawa, N., Funahashi, S., Jiang, L., Hirayama, T., Nagasawa, H., Toyokuni, S., Histological detection of catalytic ferrous iron with the selective turn-on fluorescent probe RhoNox-1 in a Fenton reaction-based rat renal carcinogenesis model. Free Radic. Res. 48 (2014), 990–995.
178. [178] Ito, F., Nishiyama, T., Shi, L., Mori, M., Hirayama, T., Nagasawa, H., Yasui, H., Toyokuni, S., Contrasting intra- and extracellular distribution of catalytic ferrous iron in ovalbumin-induced peritonitis. Biochem. Biophys. Res. Commun. 476 (2016), 600–606.
179. [179] Finazzi, D., Arosio, P., Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch. Toxicol. 88 (2014), 1787–1802.
180. [180] Dowdle, W.E., Nyfeler, B., Nagel, J., Elling, R.A., Liu, S., Triantafellow, E., Menon, S., Wang, Z., Honda, A., Pardee, G., Cantwell, J., Luu, C., Cornella-Taracido, I., Harrington, E., Fekkes, P., Lei, H., Fang, Q., Digan, M.E., Burdick, D., Powers, A.F., Helliwell, S.B., D'Aquin, S., Bastien, J., Wang, H., Wiederschain, D., Kuerth, J., Bergman, P., Schwalb, D., Thomas, J., Ugwonali, S., Harbinski, F., Tallarico, J., Wilson, C.J., Myer, V.E., Porter, J.A., Bussiere, D.E., Finan, P.M., Labow, M.A., Mao, X., Hamann, L.G., Manning, B.D., Valdez, R.A., Nicholson, T., Schirle, M., Knapp, M.S., Keaney, E.P., Murphy, L.O., Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 16 (2014), 1069–1079.
181. [181] Mancias, J.D., Pontano Vaites, L., Nissim, S., Biancur, D.E., Kim, A.J., Wang, X., Liu, Y., Goessling, W., Kimmelman, A.C., Harper, J.W., Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. eLife, 4, 2015, e10308, 10.7554/eLife.10308.
182. [182] Bienfait, H.F., van den Briel, M.L., Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen. Biochim. Biophys. Acta 631 (1980), 507–510.
183. [183] Biemond, P., Swaak, A.J., Beindorff, C.M., Koster, J.F., Superoxide-dependent and -independent mechanisms of iron mobilization from ferritin by xanthine oxidase. Implications for oxygen-free-radical-induced tissue destruction during ischaemia and inflammation. Biochem. J. 239 (1986), 169–173.
184. [184] De Domenico, I., Vaughn, M.B., Li, L., Bagley, D., Musci, G., Ward, D.M., Kaplan, J., Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J. 25 (2006), 5396–5404.
185. [185] Crichton, R.R., Roman, F., Roland, F., Iron mobilization from ferritin by chelating agents. J. Inorg. Biochem. 13 (1980), 305–316.
186. [186] Qi, Y., Jamindar, T.M., Dawson, G., Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J. Neurochem. 64 (1995), 2458–2464.
187. [187] Siegert, I., Schodel, J., Nairz, M., Schatz, V., Dettmer, K., Dick, C., Kalucka, J., Franke, K., Ehrenschwender, M., Schley, G., Beneke, A., Sutter, J., Moll, M., Hellerbrand, C., Wielockx, B., Katschinski, D.M., Lang, R., Galy, B., Hentze, M.W., Koivunen, P., Oefner, P.J., Bogdan, C., Weiss, G., Willam, C., Jantsch, J., Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1alpha upon LPS activation in the presence of ample oxygen. Cell Rep. 13 (2015), 2048–2055.
188. [188] Beckman, J., Koppenol, W., Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271:5 Pt 1 (1996), C1424–C1437.
189. [189] Radi, R., Peroxynitrite, a stealthy biological oxidant. J. Biol. Chem. 288 (2013), 26464–26472.
190. [190] Speckmann, B., Steinbrenner, H., Grune, T., Klotz, L.-O., Peroxynitrite: from interception to signaling. Arch. Biochem. Biophys. 595 (2016), 153–160.
191. [191] Denicola, A., Freeman, B.A., Trujillo, M., Radi, R., Peroxynitrite reaction with carbon dioxide/bicarbonate: kinetics and influence on peroxynitrite-mediated oxidations. Arch. Biochem. Biophys. 333 (1996), 49–58.
192. [192] Medinas, D.B., Cerchiaro, G., Trindade, D.F., Augusto, O., The carbonate radical and related oxidants derived from bicarbonate buffer. IUBMB Life 59 (2007), 255–262.
193. [193] Burke, A.J., Sullivan, F.J., Giles, F.J., Glynn, S.A., The yin and yang of nitric oxide in cancer progression. Carcinogenesis 34 (2013), 503–512.
194. [194] Grimm, E.A., Sikora, A.G., Ekmekcioglu, S., Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin. Cancer Res. 19 (2013), 5557–5563.
195. [195] Watts, R.N., Hawkins, C., Ponka, P., Richardson, D.R., Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc. Natl. Acad. Sci. USA 103 (2006), 7670–7675.
196. [196] Ida, T., Sawa, T., Ihara, H., Tsuchiya, Y., Watanabe, Y., Kumagai, Y., Suematsu, M., Motohashi, H., Fujii, S., Matsunaga, T., Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc. Natl. Acad. Sci. USA 111 (2014), 7606–7611.
197. [197] Fujii, S., Sawa, T., Nishida, M., Ihara, H., Ida, T., Motohashi, H., Akaike, T., Redox signaling regulated by an electrophilic cyclic nucleotide and reactive cysteine persulfides. Arch. Biochem. Biophys. 595 (2016), 140–146.
198. [198] Naito, Y., Takagi, T., Uchiyama, K., Katada, K., Yoshikawa, T., Multiple targets of carbon monoxide gas in the intestinal inflammation. Arch. Biochem. Biophys. 595 (2016), 147–152.
199. [199] Kabe, Y., Nakane, T., Koike, I., Yamamoto, T., Sugiura, Y., Harada, E., Sugase, K., Shimamura, T., Ohmura, M., Muraoka, K., Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat. Commun., 7, 2016, 11030.
200. [200] Cahill, M.A., Jazayeri, J.A., Catalano, S.M., Toyokuni, S., Kovacevic, Z., Richardson, D.R., The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochim. Biophys. Acta 2016 (1866), 339–349.
201. [201] Cadet, J., Douki, T., Ravanat, J.L., Oxidatively generated damage to cellular DNA by UVB and UVA radiation. Photochem. Photobiol. 91 (2015), 140–155.
202. [202] Sen, S., Kawahara, B., Mahata, S.K., Tsai, R., Yoon, A., Hwang, L., Hu-Moore, K., Villanueva, C., Vajihuddin, A., Parameshwar, P., You, M., Bhaskar, D.L., Gomez, O., Faull, K.F., Farias-Eisner, R., Chaudhuri, G., Cystathionine: a novel oncometabolite in human breast cancer. Arch. Biochem. Biophys. 604 (2016), 95–102.
203. [203] Gray, M.W., Mosaic nature of the mitochondrial proteome: implications for the origin and evolution of mitochondria. Proc. Natl. Acad. Sci. USA 112 (2015), 10133–10138.
204. [204] Dailey, H.A., Meissner, P.N., Erythroid heme biosynthesis and its disorders. Cold Spring Harb. Persp. Med., 3, 2013, a011676.
205. [205] Maio, N., Rouault, T.A., Iron–sulfur cluster biogenesis in mammalian cells: new insights into the molecular mechanisms of cluster delivery. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 1853 (2015), 1493–1512.
206. [206] White, E., Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12 (2012), 401–410.
207. [207] Boland, M.L., Chourasia, A.H., Macleod, K.F., Mitochondrial dysfunction in cancer. Front. Oncol., 3, 2013, 292.
208. [208] Paradkar, P.N., Zumbrennen, K.B., Paw, B.H., Ward, D.M., Kaplan, J., Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell. Biol. 29:4 (2009), 1007–1016.
209. [209] Levi, S., Arosio, P., Mitochondrial ferritin. Int. J. Biochem. Cell Biol. 36 (2004), 1887–1889.
210. [210] Hung, H.-I., Schwartz, J.M., Maldonado, E.N., Lemasters, J.J., Nieminen, A.-L., Mitoferrin-2-dependent mitochondrial iron uptake sensitizes human head and neck squamous carcinoma cells to photodynamic therapy. J. Biol. Chem. 288 (2013), 677–686.
211. [211] Maio, N., Rouault, T.A., Iron-sulfur cluster biogenesis in mammalian cells: new insights into the molecular mechanisms of cluster delivery. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 1853 (2015), 1493–1512.
212. [212] Yuan, X., Fleming, M.D., Hamza, I., Heme transport and erythropoiesis. Curr. Opin. Chem. Biol. 17 (2013), 204–211.
213. [213] Hada, H., Shiraki, T., Watanabe-Matsui, M., Igarashi, K., Hemopexin-dependent heme uptake via endocytosis regulates the Bach1 transcription repressor and heme oxygenase gene activation. Biochim. Biophys. Acta 1840 (2014), 2351–2360.
214. [214] Hooda, J., Cadinu, D., Alam, M.M., Shah, A., Cao, T.M., Sullivan, L.A., Brekken, R., Zhang, L., Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS One, 8, 2013, e63402.
215. [215] Latorre-Pellicer, A., Moreno-Loshuertos, R., Lechuga-Vieco, A.V., Sanchez-Cabo, F., Torroja, C., Acin-Perez, R., Calvo, E., Aix, E., Gonzalez-Guerra, A., Logan, A., Bernad-Miana, M.L., Romanos, E., Cruz, R., Cogliati, S., Sobrino, B., Carracedo, A., Perez-Martos, A., Fernandez-Silva, P., Ruiz-Cabello, J., Murphy, M.P., Flores, I., Vazquez, J., Enriquez, J.A., Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature 535 (2016), 561–565.
216. [216] Nishikawa, M., Nishiguchi, S., Shiomi, S., Tamori, A., Koh, N., Takeda, T., Kubo, S., Hirohashi, K., Kinoshita, H., Sato, E., Inoue, M., Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res. 61 (2001), 1843–1845.
217. [217] McMahon, S., LaFramboise, T., Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. Carcinogenesis 35 (2014), 1046–1054.
218. [218] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
219. [219] Kulshrestha, A., Katara, G.K., Ibrahim, S., Pamarthy, S., Jaiswal, M.K., Sachs, A.G., Beaman, K.D., Vacuolar ATPase ‘a2’ isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget 6 (2015), 3797–3810.
220. [220] Beaman, K.D., Jaiswal, M.K., Katara, G.K., Kulshreshta, A., Pamarthy, S., Ibrahim, S., Kwak-Kim, J., Gilman-Sachs, A., Pregnancy is a model for tumors, not transplantation. Am. J. Reprod. Immunol. 76 (2016), 3–7.
221. [221] Tortorella, S., Karagiannis, T.C., Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J. Membr. Biol. 247 (2014), 291–307.
222. [222] Gambling, L., Lang, C., McArdle, H.J., Fetal regulation of iron transport during pregnancy. Am. J. Clin. Nutr. 94:6 Suppl (2011), 1903S–1907S.
223. [223] Gunshin, H., Fujiwara, Y., Custodio, A., Direnzo, C., Robine, S., Andrews, N., Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J. Clin. Invest. 115 (2005), 1258–1266.
224. [224] Yang, J., Goetz, D., Li, J.-Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., An iron delivery pathway mediated by a lipocalin. Mol. Cell 10 (2002), 1045–1056.
225. [225] Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., Akira, S., Aderem, A., Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432 (2004), 917–921.
226. [226] Devireddy, L.R., Hart, D.O., Goetz, D.H., Green, M.R., A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 141 (2010), 1006–1017.
227. [227] Yang, J., Bielenberg, D.R., Rodig, S.J., Doiron, R., Clifton, M.C., Kung, A.L., Strong, R.K., Zurakowski, D., Moses, M.A., Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA 106 (2009), 3913–3918.
228. [228] Yang, J., Moses, M.A., Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 8:15 (2009), 2347–2352.
229. [229] Rodvold, J.J., Mahadevan, N.R., Zanetti, M., Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 316 (2012), 132–138.
230. [230] Ding, G., Fang, J., Tong, S., Qu, L., Jiang, H., Ding, Q., Liu, J., Over‐expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Prostate 75 (2015), 957–968.
231. [231] Ostfeld, R.S., Keesing, F., Biodiversity and disease risk: the case of Lyme disease. Conserv. Biol. 14 (2000), 722–728.
232. [232] Schoenfeld, J.D., Sibenaller, Z.A., Mapuskar, K.A., Wagner, B.A., Cramer-Morales, K.L., Furqan, M., Sandhu, S., Carlisle, T.L., Smith, M.C., Abu Hejleh, T., Berg, D.J., Zhang, J., Keech, J., Parekh, K.R., Bhatia, S., Monga, V., Bodeker, K.L., Ahmann, L., Vollstedt, S., Brown, H., Shanahan Kauffman, E.P., Schall, M.E., Hohl, R.J., Clamon, G.H., Greenlee, J.D., Howard, M.A., Shultz, M.K., Smith, B.J., Riley, D.P., Domann, F.E., Cullen, J.J., Buettner, G.R., Buatti, J.M., Spitz, D.R., Allen, B.G., O2- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31 (2017), 487–500, 10.1016/j.freeradbiomed.2017.04.001.
233. [233] Sciegienka, S.J., Solst, S.R., Falls, K.C., Schoenfeld, J.D., Klinger, A.R., Ross, N.L., Rodman, S.N., Spitz, D.R., Fath, M.A., D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress. Free Radic. Biol. Med. 108 (2017), 354–361, 10.1016/j.ccell.2017.02.018.
234. [234] Du, J., Cullen, J.J., Buettner, G.R., Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta (BBA) Rev. Cancer 1826 (2012), 443–457.
235. [235] Minor, E.A., Young, J.I., Wang, G., Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 288 (2013), 13669–13674.
236. [236] Young, J.I., Zuchner, S., Wang, G., Regulation of the epigenome by vitamin C. Annu. Rev. Nutr. 35 (2015), 545–564.
237. [237] Dickson, K.M., Gustafson, C.B., Young, J.I., Züchner, S., Wang, G., Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate. Biochem. Biophys. Res. Commun. 439 (2013), 522–527.
238. [238] Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468 (2010), 839–843.
239. [239] Jin, S.-G., Jiang, Y., Qiu, R., Rauch, T.A., Wang, Y., Schackert, G., Krex, D., Lu, Q., Pfeifer, G.P., 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 71 (2011), 7360–7365.
240. [240] Kudo, Y., Tateishi, K., Yamamoto, K., Yamamoto, S., Asaoka, Y., Ijichi, H., Nagae, G., Yoshida, H., Aburatani, H., Koike, K., Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103 (2012), 670–676.
241. [241] Yang, H., Liu, Y., Bai, F., Zhang, J., Ma, S., Liu, J., Xu, Z., Zhu, H., Ling, Z., Ye, D., Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32 (2013), 663–669.
242. [242] Luo, J., Shen, L., Zheng, D., Association between vitamin C intake and lung cancer: a dose-response meta-analysis. Sci. Rep., 4, 2014, 6161, 10.1038/srep06161.
243. [243] Creagan, E.T., Moertel, C.G., O'Fallon, J.R., Schutt, A.J., O'Connell, M.J., Rubin, J., Frytak, S., Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N. Engl. J. Med. 301 (1979), 687–690.
244. [244] Stephenson, C.M., Levin, R.D., Spector, T., Lis, C.G., Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother. Pharmacol. 72 (2013), 139–146.
245. [245] Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., Chen, Q., High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med., 6, 2014, 222ra18.
246. [246] Hoffer, L.J., Robitaille, L., Zakarian, R., Melnychuk, D., Kavan, P., Agulnik, J., Cohen, V., Small, D., Miller, W.H. Jr., High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One, 10, 2015, e0120228.
247. [247] Yun, J., Mullarky, E., Lu, C., Bosch, K.N., Kavalier, A., Rivera, K., Roper, J., Chio, I.I., Giannopoulou, E.G., Rago, C., Muley, A., Asara, J.M., Paik, J., Elemento, O., Chen, Z., Pappin, D.J., Dow, L.E., Papadopoulos, N., Gross, S.S., Cantley, L.C., Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350 (2015), 1391–1396.
248. [248] Wilkes, J., Allen, B., Berg, D.J., Wagner, B.A., Du, J., Bodeker, K., Ahmann, L., Vollstedt, S., Brown, H., Alexander, M., Cullen, J., Preliminary results of a phase I study of pharmacological ascorbate (P-AscH-) with gemcitabine chemotherapy in pancreatic cancer. Free Radic. Biol. Med., 100, 2016, S132.
249. [249] Fridman, G., Friedman, G., Gutsol, A., Shekhter, A.B., Vasilets, V.N., Fridman, A., Applied plasma medicine. Plasma Process. Polym. 5 (2008), 503–533.
250. [250] Kalghatgi, S., Kelly, C.M., Cerchar, E., Torabi, B., Alekseev, O., Fridman, A., Friedman, G., Azizkhan-Clifford, J., Effects of non-thermal plasma on mammalian cells. PLoS One, 6, 2011, e16270.
251. [251] Tanaka, H., Mizuno, M., Toyokuni, S., Maruyama, S., Kodera, Y., Terasaki, H., Adachi, T., Kato, M., Kikkawa, F., Hori, M., Cancer therapy using non-thermal atmospheric pressure plasma with ultra-high electron density. Phys. Plasmas, 22(12), 2015, 122004.
252. [252] Kajiyama, H., Utsumi, F., Nakamura, K., Tanaka, H., Toyokuni, S., Hori, M., Kikkawa, F., Future perspective of strategic non-thermal plasma therapy for cancer treatment. J. Clin. Biochem. Nutr. 60 (2017), 33–38.
253. [253] Hori, M., Choi, E.H., Toyokuni, S., Low-temperature plasma in biology and medicine. Arch. Biochem. Biophys. 605 (2016), 1–2.
254. [254] Kaneko, T., Sasaki, S., Takashima, K., Kanzaki, M., Gas-liquid interfacial plasmas producing reactive species for cell membrane permeabilization. J. Clin. Biochem. Nutr. 60 (2017), 3–11.
255. [255] Rehman, M.U., Jawaid, P., Uchiyama, H., Kondo, T., Comparison of free radicals formation induced by cold atmospheric plasma, ultrasound, and ionizing radiation. Arch. Biochem. Biophys. 605 (2016), 19–25.
256. [256] Okazaki, Y., Wang, Y., Tanaka, H., Mizuno, M., Nakamura, K., Kajiyama, H., Kano, H., Uchida, K., Kikkawa, F., Hori, M., Direct exposure of non-equilibrium atmospheric pressure plasma confers simultaneous oxidative and ultraviolet modifications in biomolecules. J. Clin. Biochem. Nutr. 55 (2014), 207–215.
257. [257] Isbary, G., Morfill, G., Schmidt, H.U., Georgi, M., Ramrath, K., Heinlin, J., Karrer, S., Landthaler, M., Shimizu, T., Steffes, B., A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. Br. J. Dermatol. 163 (2010), 78–82.
258. [258] Miyamoto, K., Ikehara, S., Sakakita, H., Ikehara, Y., Low temperature plasma equipment applied on surgical hemostasis and wound healings. J. Clin. Biochem. Nutr. 60 (2017), 25–28.
259. [259] Iseki, S., Nakamura, K., Hayashi, M., Tanaka, H., Kondo, H., Kajiyama, H., Kano, H., Kikkawa, F., Hori, M., Selective killing of ovarian cancer cells through induction of apoptosis by nonequilibrium atmospheric pressure plasma. Appl. Phys. Lett., 100, 2012, 113702.
260. [260] Utsumi, F., Kajiyama, H., Nakamura, K., Tanaka, H., Mizuno, M., Ishikawa, K., Kondo, H., Kano, H., Hori, M., Kikkawa, F., Effect of indirect non-equilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo. PLoS One, 8, 2013, e81576.
261. [261] Shi, L., Wang, Y., Ito, F., Okazaki, Y., Tanaka, H., Mizuno, M., Hori, M., Richardson, D.R., Toyokuni, S., Biphasic effects of l-ascorbate on the tumoricidal activity of non-thermal plasma against malignant mesothelioma cells. Arch. Biochem. Biophys. 605 (2016), 109–116.
262. [262] Ye, F., Kaneko, H., Nagasaka, Y., Ijima, R., Nakamura, K., Nagaya, M., Takayama, K., Kajiyama, H., Senga, T., Tanaka, H., Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration. Sci. Rep., 5, 2015, 7705.
263. [263] Tanaka, H., Mizuno, M., Ishikawa, K., Nakamura, K., Kajiyama, H., Kano, H., Kikkawa, F., Hori, M., Plasma-activated medium selectively kills glioblastoma brain tumor cells by down-regulating a survival signaling molecule, AKT kinase. Plasma Med. 1 (2011), 265–277.
264. [264] Yanatori, I., Yasui, Y., Tabuchi, M., Kishi, F., Chaperone protein involved in transmembrane transport of iron. Biochem. J. 462 (2014), 25–37.
265. [265] Yanatori, I., Richardson, D.R., Imada, K., Kishi, F., Iron export through the transporter Ferroportin 1 is modulated by the iron chaperone PCBP2. J. Biol. Chem. 291 (2016), 17303–17318.